Background: Evaluations of stress-induced cardiac functional alterations in adults after neonatal glucocorticoid (GC) treatment have been limited. In the present study, we evaluated adult cardiac functional recovery during postischemic reperfusion and measured cardiac gene expression involved energy metabolism in rats neonatally treated with dexamethasone (DEX). Method: Male Wistar rats were injected DEX in first 3 d after birth and controls were received saline (SAL). At 24 wk of age, insulin tolerance tests were performed, plasma lipid levels were measured, and left ventricular function and myocardial infarct size were evaluated. Expressions of genes involved in cardiac energy metabolism were measured by quantitative real-time polymerase chain reaction (PCR) and western blot. results: In 24-wk-old rats, neonatal DEX administration caused dyslipidemia, impaired cardiac recovery function and increased size of infarction, decreased cardiac expression of glucose transporter 4(GLUT4), peroxisome proliferative-activated receptor gamma coactivator 1α (PGC-1α) and ratios of phospho-forkhead box O1/forkhead box O1 (p-FoxO1/FoxO1) and phospho AMP-activated protein kinase/AMP-activated protein kinase (p-AMPK/AMPK) but increased pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) expression compared with controls. conclusion: Neonatal DEX administration impairs cardiac functional recovery during reperfusion following ischemia in 24-wk-old rats. Reduced cardiac glucose utilization may contribute to the long-term detrimental effects caused by neonatal DEX treatment.
g lucocorticoids (GCs) exhibit anti-inflammatory effects and have been widely used in western countries to treat chronic lung disease in premature infants since the 1970s. In spite of their short-term benefits, concerns have emerged regarding their long-term effects, including growth retardation (1), neurologic defect (2) , increased blood pressure, and renal damage (1) .
Extensive data indicate that cardiovascular diseases can be "programmed" by early life factors. Previous studies in rats have demonstrated that neonatal dexamethasone (DEX) administration may cause cardiac dilation and depressed cardiac systolic function at 4 wk of age (5) , and cardiac dysfunction at about 14 wk of age (3) , suggesting that neonatal GC administration may have long-term negative effects on cardiac function. Functional evaluation of the heart of adult animals neonatally treated with GCs has been performed by Niu et al. (3) previously but data are still limited.
The heart requires a continuous energy supply to maintain its ability to pump. Mammalian hearts derive about 70% of their energy from fatty acid oxidation and about 30% from glucose after birth. Disruptions in energy supply and alterations in energy substrate utilization have been found correlated with cardiac pathophysiological conditions, which combined with impaired cardiac functionality, increased susceptibility to ischemia-reperfusion (I/R) injury and impaired functional recovery following I/R (6) . Mitochondria are the site of energy metabolism, and alterations in mitochondrial architecture and mitochondrial dysfunction have been linked to several heart disorders (7) . Previous data also indicate that cardiac mitochondrial disorders may be "programmed" by early life factors such as intrauterine growth restriction or maternal overnutrition (8) , predisposing cardiac abnormalities in later life. The effects of neonatal GC administration on cardiac energy metabolism have been studied in rats from 2 to 14 d of age (9) , but little research has been undertaken regarding the effects of this therapeutic strategy on cardiac energy metabolism in adult rats.
Therefore, we hypothesize that neonatal GC administration impairs cardiac function in adults by disturbing cardiac energy metabolism.
RESULTS
The Effects of Neonatal DEX Administration on Body Weight, Heart Weight, and Serum Levels of Glucose and Lipids
In the present study, we observed that neonatal DEX administration caused growth retardation in rats (Figure 1 ). Significant reductions in body weight were noted before 14 wk of age in the group treated with DEX compared with age-matched SALtreated controls (DEX vs. SAL: P < 0.05). The body weights of Articles the DEX-treated animals appeared to be lower than those of the controls after 14 wk but this difference was not significant.
In the present experiment, there were no statistical differences found in body weight, total and relative heart weight at 24 wk of age between saline (SAL) and DEX-treated rats ( Table 1 , DEX vs. SAL: all P > 0.05), indicating neonatal DEX treatment could not cause permanent growth retardation and apparent cardiac hypertrophy.
Neonatal DEX administration caused significant increases in serum total cholesterol and nonesterified fatty acid levels in 24-wk-old rats compared with the control group ( Table 1 , DEX vs. SAL: P < 0.05) but did not affect the levels of fasting blood glucose or serum triglycerides ( Table 1 , DEX vs. SAL: P > 0.05).
The Effects of Neonatal DEX Administration on Insulin Testing in 24-wk-Old Rats
Insulin tolerance testing was performed to check insulin resistance. With the exception of higher glucose levels noted at 1 h following insulin injections (Figure 2 ; DEX vs. SAL: P < 0.05), neonatal DEX treatment did not result in altered glucose levels at either 30 min or 2 h compared with SAL-treated controls. (Figure 3a,c,d ), whereas LVEDP was increased in both groups (Figure 3b) , suggesting that left ventricular function was decreased. However, the changes in left ventricular function were significantly aggravated in the DEX group compared with the control group. Recovery of LVDP, +(LVdP/dt) max , −(LVdP/ dt) max and LVEDP following I/R was less successful in DEXtreated rats than in SAL-treated rats (Figure 3 ) (DEX vs. SAL: P < 0.05 or P < 0.01), suggesting greater functional recovery impairment in DEX-treated rats. Each of these findings suggests that DEX treatment has detrimental long-term effects on the heart. Infarct sizes induced by I/R were found larger in DEX-treated animals when compared with age-matched controls (Figure 4a,b) .
Neonatal DEX Treatment Causes Mitochondrial Destruction in the Cardiomyocytes of 24-wk-Old Rats
Ultrastructural analyses of cardiomyocytes via transmission electron microscope (TEM) revealed that neonatal DEX treatment caused mitochondrial structural abnormalities at 24 wk of age. These abnormalities were characterized by marked changes in the architecture of the cristae, including fragmented and tubular cristae, as well as the loss of cristae ( Figure 5 ). Values are expressed as the means ± SD (n = 6 per treatment group). Student's T-test was used to check the differences between two groups. *P < 0.05 DEX vs. age-matched SAL-treated controls. DEX, dexamethasone; NEFA, nonesterified fatty acids; SAL, saline. Neonatal DEX administration significantly increased cardiac pyruvate dehydrogenase kinase isoenzyme 4 (pdk4) but decreased glucose transporter4 (glut4) gene expression at both mRNA ( Figure 6 ; DEX vs. SAL: P < 0.05) and protein levels (Figure 7 ; DEX vs. SAL: P < 0.05). Increased cardiac carnitine palmitoyltransferase 1b (cpt1b) gene expression at the mRNA level was observed in DEX-treated rats (Figure 6 ), but no apparent alterations in CPT1B protein content were noted between the two groups (Figure 7 ; DEX vs. SAL: P > 0.05). 
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Compared with age-matched controls, DEX treatment resulted in slightly higher cardiac forkhead box O1 (FoxO1) expression at both mRNA (Figure 6 ; DEX vs. SAL: P < 0.05) and protein levels (Figure 7 ; DEX vs. SAL: P < 0.05), but no differences were noted in phospho-FoxO1 (p-FoxO1) levels between the two groups (Figure 7a) , resulting in significantly reduced ratios of p-FoxO1/FoxO1 (Figure 7b ; DEX vs. SAL: P < 0.05).
Neonatal DEX administration also caused significant reductions in cardiac peroxisome proliferative activated receptor, gamma, coactivator 1α (PGC-1α) expression at both mRNA (Figure 6 ; DEX vs. SAL: P < 0.05) and protein levels (Figure 7 ; DEX vs. SAL: P < 0.05) compared with SAL-treated controls.
Neonatal DEX treatment had no effects on cardiac AMPactivated protein kinase (ampk) gene expression at either the mRNA (Figure 6 ) or protein levels compared with SAL-treated rats (Figure 7 ; DEX vs. SAL: P > 0.05). Significantly, reductions in cardiac phospho-AMPK (p-AMPK) protein content were noted in DEX-treated rats (Figure 7 ; DEX vs. SAL: P < 0.05) and these reductions resulted in significantly lower cardiac ratios of p-AMPK/AMPK (Figure 7b ; DEX vs. SAL: P < 0.05).
DISCUSSION
Synthetic glucocorticoid DEX has been used to treat chronic lung disease in preterm infants with respiratory distress syndrome since the 1970s, and great concern has emerged regarding its long-term negative effects (10) . Growth retardation is one of the consequences of early-life DEX exposure and has been observed both clinically and experimentally (1,11). Our results indicated that DEX-treated rats had significantly lower body weights than SAL-treated rats up to 14 wk of age, and no reduced body weight mentioned afterwards, indicating neonatal DEX administration may cause transient growth retardation, and there might exit a catch-up body weight gain in adult life. Previous studies described lower heart weights in rats aged 50 wk following neonatal DEX administration (12) . However, in the present experiment, no alterations in relative Figure 6 . Effects of neonatal DEX treatment on relative expression of cardiac genes involved in energy metabolism at 24 wk of age at mRNA level. n = 6 per group. Gene expression levels were calculated by 2 -ΔΔCt method and standardized against gapdh mRNA. Student's T-test was used to check the differences between two groups. *P < 0.05 DEX vs. SAL-treated control. SAL: white bar; DEX: black bar. DEX, dexamethasone; SAL, saline. Articles Jiang et al.
heart weight were observed following neonatal DEX treatment at 24 wk of age, indicating there might no apparent cardiac hypertrophy or relative cardiac growth retardation were noted in this age group. Metabolic disorders are one of the long-term negative consequences of early GC treatment. Prenatal GC administration may cause metabolic disorders such as insulin resistance (13) and diabetes (14) , in the offspring. However, data regarding the effects of neonatal GC treatment on glucose levels, lipid levels, and insulin sensitivity in adult animal models are rare. In this study, we observed that neonatal DEX treatment caused significantly higher serum nonesterified fatty acid and total cholesterol levels in 24-wk-old rats, suggesting that neonatal GC treatment may cause dyslipidemia in adult. However, no hyperglycemia was observed among 24-wk-old DEX-treated rats in the present study. In combination with similar blood glucose level observations in a previous study of the same animal model at 50 wk of age (1), these results suggest that neonatal DEX administration may not cause alterations in fasting blood glucose levels during adulthood.
Insulin tolerance tests performed in 24-wk-old rats revealed higher blood glucose levels at 1 h after insulin injection in DEXtreated animals, indicating that insulin resistance may occur at this age. Adigun et al. (15) reported that neonatal DEX treatment might increase hepatic levels of adenylyl cyclase in rats at 75 d of age. Adenylyl cyclase synthesizes cyclic AMP from ATP and functions as a second messenger controlling hepatic gluconeogenesis and glycogenolysis. Therefore, hepatic insulin resistance may occur in this model, but further study is warranted.
Recent studies have indicated that cardiac susceptibility to I/R injury in adults can be "programmed" by unfavorable maternal factors such as low protein diet (16) and maternal obesity (17) . Studies evaluating cardiac function during adulthood after neonatal GC administration are quite limited. Human follow-up studies in school-age children have not found any cardiac functional abnormalities (18) , but the long-term effects appear to be noteworthy (19) . In previous studies, reduced systolic function was noted in 4-wk-old rats (20) and impaired cardiac function was noted in adult rats (3) after neonatal DEX treatment.
In the present study, we found that although the function of hearts isolated from DEX-treated rats and SAL-treated rats was comparable before I/R, the cardiac recovery ability during I/R was drastically impaired in the DEX-treated group. Therefore, although neonatal DEX administration does not cause significant alterations in cardiac performance under "normal" physiological conditions at 24 wk of age, it may increase cardiac vulnerability to I/R injury and reduce cardiac function under stress. Previous study performed by Niu et al. (3) indicated that neonatal DEX administration caused reduced cardiac output response to afterload in adult rats. Combined with the results from this study, there might be a big possibility that neonatal DEX administration may impair cardiac working potential under stress such as overload and I/R.
The beating heart requires a continuous energy supply to maintain its contractile function, and unfavorable energy substrate utilization correlates with the development of cardiomyopathy (21) . In the present study, neonatal DEX administration decreased cardiac GLUT4 expression but increased PDK4 expression at the protein level, suggesting reduced cardiac glucose uptake and oxidation. Diabetic hearts are characterized by reduced glucose oxidation and increased fatty acid utilization and are more prone to I/R injury (6). Post-I/R cardiac functional recovery may be improved by partially inhibiting fatty acid oxidation or by stimulating glucose oxidation (22, 23) . Therefore, decreased cardiac glucose oxidation caused by neonatal DEX treatment may contribute to reduced cardiac post-I/R functional recovery in 24-wk-old rats.
FoxO1 is a transcription factor involved in many cellular processes via the targeting of downstream genes such as PDK4 (24) . Phosphorylated FoxO1 can export from the nucleus and loses its transcriptional activity. Elevated cardiac FoxO1 levels may exert protective effects in some cardiomyopathies (25) but appear to be detrimental in diabetic hearts due to blunted cardiac insulin sensitivity and increased PDK4 gene expression (26) . In the present study, we observed that neonatal DEX administration resulted in increased cardiac total FoxO1 and decreased p-FoxO1 protein content in 24-wk-old rats, indicating that elevated levels of activated FoxO1 may contribute to elevated levels of downstream PDK4 expression.
AMPK orchestrates cellular responses to a variety of stressors and regulates metabolism and organelle functions. Recent investigations have shed light on the cardioprotective role of AMPK during I/R injury and pathological hypertrophy and heart failure (27) . AMPK is activated by phosphorylation of Thr172, which leads to the activation of downstream target genes such as FoxO and PGC-1α (28) and triggering the signaling pathways. Data from the present experiment demonstrated that neonatal DEX administration did not cause alterations in AMPK gene expression lead to decreased cardiac p-AMPK/AMPK ratio in rats, which may contribute to decreases in PGC-1α and p-FoxO1/FoxO1 protein levels.
Mitochondria are responsible for energy metabolism. Metabolic defects such as hyperlipidemia and insulin resistance may impair cardiac functional recovery post-I/R by attenuating mitochondrial biogenesis (29) , enhancing oxidative stress, (30) and causing intracellular Ca(2+)-overload (31) . Mitochondria may also be affected by early-life factors (32) . In the present study, neonatal DEX administration caused mitochondrial architectural defects in 24-wk-old rats. PGC-1α is an important energy regulator in the heart and may upregulate cardiac mitochondrial antioxidants such as SOD2 and Trx2 (33) and participate in mitochondriogenesis (34) . Repressed PGC-1α expression has been noted in cardiac hypertrophy, heart failure, (35, 36) and the latter stages of diabetes, in which changes in mitochondrial architecture have also been noted (37) . Impaired cardiac AMPK/PGC-1α signaling caused by hypoadiponectinemia may result in reduced mitochondrial biogenesis, rendering hearts more vulnerable to ischemic injury (29) . Metformin, an antidiabetes drug, may protect the heart against I/R damage by increasing the expression of phosphorylated AMPK and PGC-1α, which are associated with
